Vivesto AB
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIVE.ST research report →
Companywww.vivesto.com
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.
- CEO
- Erik Kinnman Assoc.
- IPO
- 2010
- Employees
- 4
- HQ
- Solna, SE
Price Chart
Valuation
- Market Cap
- $88.76M
- P/E
- -415.23
- P/S
- 0.00
- P/B
- 81.49
- EV/EBITDA
- -2.80
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -23.13%
- ROIC
- -19.56%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-34,082,000 · 14.27%
- EPS
- $-0.06 · 25.44%
- Op Income
- $-34,377,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $27.76
- 52W Low
- $7.00
- 50D MA
- $8.23
- 200D MA
- $13.23
- Beta
- 0.83
- Avg Volume
- 21.55K
Get TickerSpark's AI analysis on VIVE.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VIVE.ST Coverage
We haven't published any research on VIVE.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VIVE.ST Report →